Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Leukemia

Frailty

Hematologic Neoplasms

Hematologic Diseases

Acute Graft Versus Host Disease

Antineoplastic Agents

All Drugs and Chemicals

Venetoclax

Azacitidine

Decitabine

Gilteritinib

Midostaurin

Sorafenib

Ivosidenib

Clofarabine

Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care

Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy

Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.

Bone Marrow or Peripheral Blood Graft (BMT)

Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.

Cancer-directed Therapy or Best Supportive Care

Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.

Frailty Assessment

Shannon McCurdy, MD

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

NRM will be defined as death without evidence of disease progression or relapse.

NRM of frail and pre-frail patients by intensity of treatment

Abramson Cancer Center at Penn Medicine

Respiratory Tract (Lung and Bronchial) Diseases

Digestive System Diseases

Lung Neoplasms

Esophageal Neoplasms

Esophageal Cancer

Patients who will undergo surgery for lung cancer

Patients who will undergo esophagectomy for esophageal cancer

Various physiologic and frailty assessment tests

Gail E Darling, MD

Determine the feasibility of assessment of measures of frailty and determine if these measures provide a clinically important contribution of risk assessment in a population of patients undergoing major thoracic surgery for lung or esophageal cancer.

Both gastro-esophageal and lung cancers are major causes of morbidity and mortality worldwide. In Canada the incidence for Esophageal Adenocarcinoma has doubled in the last two decades, while lung cancer is the leading cause of cancer death. Surgery is a treatment option for these patients; however, esophagectomy in particular, is associated with significant morbidity, mortality and adverse effect on quality of life. Despite satisfactory standard preoperative testing to evaluate risk for surgery, some patients experience morbidity and never recover fully from surgery. Frailty assessment may offer a more sensitive measure of a patient's physiologic reserve, which may allow identification of patients who are poor candidates for surgery. There is a lack of consensus of how best to assess frailty prior to surgery. This study aims to analyze frailty assessment as a tool for patient selection for surgery.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies	NCT03680677	Leukemia, Acute MDS	Bone Marrow or ... Cancer-directed... Frailty Assessm...	60 Years -	Abramson Cancer Center at Penn Medicine
Assessment of Patient Frailty Prior to Thoracic Surgery	NCT02803281	Lung Cancer Esophageal Canc...	Frailty Assessm...	18 Years -	University Health Network, Toronto

Spots Global Cancer Trial Database for frailty assessment